Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

Androgen therapy might help some women with low libido, but it has risks and should be used carefully.

Australian doctors experienced in adult transgender healthcare mostly prescribe intramuscular testosterone and oral estradiol, recommend mental health assessments before hormone therapy, and support improved training and guidelines.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Testosterone and DHEA can benefit women's health but must be prescribed carefully due to potential risks.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

Hormonal therapy for transgender individuals carries health risks but is a personal choice.

Hormone replacement therapy may improve hair growth in the frontal hairline of postmenopausal women with hair loss.

Nourkrin® with Marilex® may significantly increase hair growth and alopecia could be an early sign of metabolic syndrome.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

Testosterone implants in women require pharmacological dosing to be effective and are generally safe and well-tolerated.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

Hormone therapy for trans individuals is effective and generally safe in the short term.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Short-acting testosterone injections in a clinic are a preferred treatment for low testosterone because they work well, are convenient, and patients stick with the treatment.

The document concludes that proper diagnosis and evidence-based treatments are crucial for managing hair diseases, and psychological support for patients is important.

Male hormones, or androgens, affect women's health in areas like mood and bone density, and hormone replacement therapy using antiandrogenic progestogens can improve mood disorders and alertness in menopausal women.

Testosterone therapy and surgeries like mastectomy improve transgender men's lives and mental health with low risks and high satisfaction.

Always consider xanthomatous hypophysitis before deciding on pituitary surgery.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Drospirenone is a unique progestin with anti-water retention and potential blood pressure benefits, used in birth control and hormone therapy.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

DHEA stimulates skin oil glands and could help postmenopausal women, with potential for acne and excessive hair growth treatments.